The 20 Largest Medical Device Companies In the World


AbbottNo. 20: Abbott

Abbott Park, Ill.

2016 RANK: 24

Revenue: $5,233,000,000*

Fiscal year ending: Dec. 31, 2016


Key Personnel:

Miles White, chairman & CEO; Hubert Allen, EVP, general counsel & secretary; Brian Blaser, EVP, diagnostics; John Capek, EVP, ventures; Robert Ford, EVP, medical devices; Stephen Fussell, EVP, HR; Andrew Lane, EVP, established pharmaceuticals; Heather Mason, EVP, nutritional; Brian Yoor, EVP, finance & CFO; Roger Bird, SVP, U.S. nutrition; Jaime Contreras, SVP, core laboratory diagnostics, commercial operations; Denis Gestin, SVP, global commercial integration; Elaine Leavenworth, SVP, chief marketing & external affairs officer; Joseph Manning, SVP, international nutrition; Corlis Murray, SVP, quality assurance, regulatory & engineering services; Daniel Salvadori, SVP, established pharmaceuticals, Latin America; Jared Watkin, SVP, diabetes.


Abbot moved from 24th to 20th in 2016, and there’s every indication that by 2018 it will have risen higher in the ranks, thanks to its $25 billion acquisition of St. Jude Medical in January 2016.

In August, the FDA approved HeartMate 3, a bridge-to-transplant cardiac assist device that pumps blood for heart-failure patients using a fully magnetically levitated impeller that simulates the beating of a heart. The HeartMate 3 device is among key products in the St. Jude Medical portfolio, along with the other major launch this year, Tacticath, a contact force enabled catheter.

And Abbott is also making moves in the diabetes space, inking a deal with Bigfoot Biomedical, integrating its FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions.

* Revenues from Abbott’s medical device segment.

Download the full Big 100 list here.

And you can also pick up a free hard copy of the Big 100 issue at DeviceTalks Boston on Oct. 2!


How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11


  1. Chris Newmarker says:

    Apologies. We had to fix a technical glitch with the Big 100 spreadsheet download. If you fill out the sign-up form now, you should get an email with a link to download the spreadsheet, instead of last year’s Big 100 edition.

  2. Chris, Thank you for the update. I just downloaded the Big 100.

Speak Your Mind